论文部分内容阅读
作者研究了雷帕霉素（rapamycin;RPM）对C57BL/6J→BALB/c小鼠心肌和皮肤移植的抗移植排斥作用,结果表明 RPM比目前应用于临床器官移植的环孢菌素（Cyclosporine A;CsA）具有更好的抗移植排斥作用。此外还观察了 RPM对正在进行的移植心肌排斥反应的作用,RPM于小鼠心肌移植后第 7天开始给药与0天开始给药组相比较,移植心肌的平均存活天数无明显差异,表明RPM对心肌移植排斥反应有很好的治疗作用。小剂量的RPM与亚治疗剂量的CsA合用还有很好的协同作用。
The authors investigated the anti-transplant rejection of rapamycin (RPM) on myocardium and skin grafts in C57BL / 6J → BALB / c mice. The results show that RPM is superior to the cyclosporine A ; CsA) has a better anti-transplant rejection. In addition, the effect of RPM on the ongoing myocardial allograft rejection was also observed. There was no significant difference in the mean number of days surviving for myocardial transplants when RPM was administered on the 7th day after myocardial transplantation in mice as compared with the group started on day 0 RPM has a good therapeutic effect on myocardial transplant rejection. There is also a good synergy between low dose RPM and subtherapeutic doses of CsA.